New pill shows promise for kidney disease patients
NCT ID NCT06670352
First seen May 29, 2026 · Last updated Jun 19, 2026 · Updated 6 times
Summary
This study tested a new drug called HSK39297 in 87 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug could lower protein levels in urine, a sign of kidney damage, compared to a placebo. Participants took the drug or placebo for up to 24 weeks, and researchers measured changes in urine protein.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210000, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.